Diplomat Pharmacy (DPLO) Misses Q3 EPS by 22c, Updates Guidance

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.00, $0.22 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.42 billion.

GUIDANCE:

Diplomat Pharmacy sees 2018 EPS of ($0.10)-$0.03, versus the consensus of $0.83. Diplomat Pharmacy sees 2018 revenue of $5.5-5.7 billion, versus the consensus of $5.64 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c